Meds & supplements › Capmatinib
Medicine
Capmatinib
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved…
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved…
What it is used for
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Side effects, and when to stop
The following clinically significant adverse reactions are described elsewhere in the labeling:
- ILD/Pneumonitis
- Hepatotoxicity
- Pancreatic Toxicity
- Hypersensitivity reactions
Who should not take it
None.
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Capmatinib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/capmatinib
- APA 7th
sofidex. (2026, August 2). Capmatinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/capmatinib
- AMA 11th
Capmatinib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/capmatinib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.